La galena coment que diversos estudios revelaron que la semaglutida solo bajaba la glicemia en pacientes diabticos y que el riesgo de hipoglucin (bajn de azcar) era muy mnimo en pacientes no diabticos , por tanto, se autoriz la comercializacin de otro GLP, la liraglutida ( Saxenda ) que est comercializado para perder peso y est aprobado para perder peso
The dark appearance of the patches suggest that the acute phase has passed
Think of it as precision medicine for your microbiome
"Eli Lilly to buy gene therapy developer Prevail in about $1 billion deal"
Given that sensory or gastrointestinal adverse effects, such as dysgeusia and persistent nausea, can impair nutritional intake and lead to early treatment discontinuation (particularly in vulnerable populations) future research must incorporate rigorous sensory testing, larger and more diverse cohorts, and adherence-related outcomes to clarify how incretin therapies influence taste perception and long-term eating behavior (153, 157, 161)